Viruses in cancer treatment

• Published in: Clinical & translational oncology Vol. 15; no. 3; pp. 182 - 188
• Main Author: Alemany, R.
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 01.03.2013
• Subjects: Animals; Humans; Medicine; Medicine & Public Health; Neoplasms - immunology; Neoplasms - therapy; Oncology; Oncolytic Virotherapy; Oncolytic Viruses - physiology; Special Article; Virus; Oncolytic; Immunotherapy; Virotherapy
• ISSN: 1699-048X; 1699-3055
• DOI: 10.1007/s12094-012-0951-7

Soon after the discovery that viruses cause human disease, started the idea of using viruses to treat cancer. After the initial indiscriminate use, crude preparations of each novel virus in the early twentieth century, a second wave of virotherapy blossomed in the 60s with purified and selected viruses. Responses were rare and short-lived. Immune rejection of the oncolytic viruses was identified as the major problem and virotherapy was abandoned. During the past two decades virotherapy has re-emerged with engineered viruses, with a trend towards using them as tumor-debulking immunostimulatory agents combined with radio or chemotherapy. Currently, oncolytic Reovirus, Herpes, and Vaccinia virus are in late phase clinical trials. Despite the renewed hope, efficacy will require improving systemic tumor targeting, overcoming stroma barriers for virus spread, and selectively stimulating immune responses against tumor antigens but not against the virus. Virotherapy history, viruses, considerations for clinical trials, and hurdles are briefly overviewed.